Potential effectiveness of a therapeutic HPV intervention campaign in Uganda
Open Access
- 6 November 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 150 (5) , 847-855
Abstract
Cervical cancer is a major source of morbidity and mortality in Uganda. In addition to prophylactic HPV vaccination, secondary prevention strategies are needed to reduce cancer burden. We evaluated the potential cancer reductions associated with a hypothetical single-contact therapeutic HPV intervention— with 70% coverage and variable efficacy [30-100%]— using a three-stage HPV modeling framework reflecting HPV and cervical cancer burden in Uganda. In the reference case, we assumed prophylactic pre-adolescent HPV vaccination starting in 2020 with 70% coverage. A one-time therapeutic intervention targeting 35-year-old women in 2025 (not age-eligible for prophylactic vaccination) averted 1,801 cervical cancers per 100,000 women over their lifetime (100% efficacy) or 533 cancers per 100,000 (30% efficacy). Benefits were considerably smaller in birth cohorts eligible for prophylactic HPV vaccination (768 cases averted per 100,000 at 100% efficacy). Evaluating the population-level impact over 40 years, we found introduction of a therapeutic intervention in 2025 with 100% efficacy targeted annually to 30-year-old women averted 139,000 incident cervical cancers in Uganda. This benefit was greatly reduced if efficacy was lower (30% efficacy; 41,000 cases averted), introduction was delayed (2040 introduction; 72,000 cases averted) or both (22,000 cases averted). We demonstrate the potential benefits of a single-contact HPV therapeutic intervention in a low-income setting, but show the importance of high therapeutic efficacy and early introduction timing relative to existing prophylactic programs. Reduced benefits from a less efficacious intervention may be somewhat offset if available within a shorter time frame.Keywords
Funding Information
- Bill and Melinda Gates Foundation
- National Cancer Institute (T32CA092203)
This publication has 32 references indexed in Scilit:
- Uptake of Cervical Cancer Screening and Associated Factors among Women in Rural Uganda: A Cross Sectional StudyPLOS ONE, 2016
- When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysisPapillomavirus Research, 2015
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialThe Lancet, 2015
- An Updated Natural History Model of Cervical Cancer: Derivation of Model ParametersAmerican Journal of Epidemiology, 2014
- Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan AfricaVaccine, 2013
- Assessing women's willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in UgandaInternational Journal of Gynecology & Obstetrics, 2011
- Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapyAmerican Journal of Obstetrics and Gynecology, 2011
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countriesVaccine, 2008
- Multiparameter Calibration of a Natural History Model of Cervical CancerAmerican Journal of Epidemiology, 2007